How to Check Specialty Drug Tier Placement on 2027 ACA Plans Before December 15 — The Tier 5 Coinsurance Trap
By HealthCalc Team
Published November 14, 2026
12 min read
Open enrollment is now midway through its second week, and the shopping variable most likely to burn a chronically-ill enrollee in 2027 is not the premium and not the deductible — it is a single digit on page 47 of a PDF almost nobody reads. Two Bronze plans can look nearly identical on HealthCare.gov. On one, your biologic sits on tier 4 with a $150/month copay. On the other, the exact same drug is on tier 5 with 40% coinsurance of the plan's $4,200 negotiated price. Over a year, that is a $150 × 12 = $1,800 bill on plan A, or a $1,680 × monthly bill on plan B until you drag yourself to the $9,525 individual out-of-pocket maximum — typically by March.
The tier structure is not random. Insurers choose where to place each drug to control utilization, and the placement can and does shift between plan years. A drug that was tier 4 on your 2026 plan may quietly land on tier 5 for 2027. Even worse, two plans from the same insurer can place the same drug on different tiers. If you are being auto-renewed into a 2027 plan, the formulary was almost certainly updated. You will not find out by looking at the plan name or the premium.
This guide walks through how to verify specialty tier placement for every prescription you take on every 2027 plan you are considering, before you click Enroll by the December 15, 2026 deadline for January 1 coverage. It also covers the three real fixes if your drug is on tier 5 of every plan you can afford.
How the 2027 formulary tier structure actually works
Most 2027 ACA plans use a four- or five-tier formulary. The structure varies by insurer but almost always maps to this pattern:
- Tier 1 (preferred generic): $0 to $10 copay. Metformin, lisinopril, levothyroxine, most SSRIs in generic form.
- Tier 2 (non-preferred generic / preferred brand): $15 to $35 copay. Newer generics, some older brands.
- Tier 3 (preferred brand): $45 to $90 copay. Brand-name drugs with no generic equivalent or where the insurer negotiated favorable pricing.
- Tier 4 (non-preferred brand / low-cost specialty): Copay ($100–$300) or sometimes coinsurance (20–30%). This is where lower-cost specialty drugs (some biosimilars, some orals for chronic conditions) often land.
- Tier 5 (specialty / high-cost): Almost always coinsurance, 30 to 50 percent of the drug's negotiated cost. This is where biologics, infused medications, cancer drugs, and most high-cost specialty therapies sit.
The critical move insurers are making in 2027: pushing more drugs from tier 4 to tier 5. The 2027 standardized plan designs at the federal level permit this as long as the plan still meets actuarial value for its metal tier. For Bronze plans with a 60% actuarial value, moving a drug from a $150 copay (tier 4) to 40% coinsurance (tier 5) raises enrollee exposure by $1,500–$2,000+ per year on each affected drug.
The five-step specialty tier verification checklist
Run this on every 2027 plan you are seriously considering. Budget 15 minutes per plan if you take a specialty drug; it is the single highest-leverage activity of open enrollment for people with chronic conditions.
1Build your drug list and pull each drug's correct name and strength
Get out your most recent prescription bottles or pharmacy app. For each specialty or chronic-use drug, record the exact generic or brand name, the strength (e.g., 40mg/0.4mL for Humira), and whether it is a biosimilar (Yusimry, Amjevita, Hadlima are biosimilars to Humira). Biosimilars and originators are different products on the formulary and are tiered differently. On many 2027 plans, the biosimilar is tier 3 and the originator is tier 5.
Also record how often you fill (monthly, every 28 days, every three months for a 90-day fill). This matters for the annual-cost calculation.
2Use the HealthCare.gov drug search in the plan comparison tool
On HealthCare.gov or your state exchange, start the plan shopping flow and when prompted, add each drug to your drug list. The tool will show, for each plan, the drug's tier and the estimated annual cost at your typical fill frequency. Note that the HealthCare.gov estimate is a point-in-time snapshot of the plan's current formulary and uses an average negotiated price, which may differ from what your pharmacy charges.
Export or screenshot the comparison for the top 5 plans by premium. You will reconcile these against the insurer's own formulary PDF next.
3Open each plan's own 2027 formulary PDF and search for your drug
On the plan details page, look for a link labeled “Formulary,” “Drug List,” or “Prescription Drug Coverage.” This downloads the insurer's official formulary as a PDF, typically 100–300 pages. Open it, press Ctrl+F (or Cmd+F on Mac), and type your drug's name. The listing shows: tier, prior authorization required (PA), step therapy required (ST), quantity limits (QL), and any gender or age restrictions.
If HealthCare.gov said tier 4 and the formulary PDF says tier 5, the PDF is authoritative. The exchange tool is refreshed periodically but not always in sync with mid-cycle formulary updates the insurer has filed. Insurers must honor the formulary PDF that is current as of January 1, 2027.
4Check prior authorization and step therapy requirements
A drug on tier 4 with prior authorization and step therapy is often harder to actually fill than a tier 5 drug without those restrictions. Prior authorization means your doctor must submit paperwork showing medical necessity before the plan covers any of the drug cost. Step therapy means you must try (and fail) one or more cheaper alternatives first.
Look at the PA/ST notations next to your drug on the formulary PDF. If you have been stable on this drug for months or years, step therapy can force you to switch to a different drug temporarily, with documented failure, before the plan will cover the one you already know works. Our step therapy appeal guide covers how to request a step therapy exception, but during enrollment you want to avoid the plan with the strictest rules when possible.
5Compute your realistic annual drug cost at the tier's full coinsurance
For each plan, compute your worst-case annual specialty drug cost:
- Find the drug's plan-negotiated price (not the retail price). HealthCare.gov's plan details often show this; if not, ask the insurer or use the manufacturer's average wholesale price minus 15–20% as an estimate.
- Apply the plan's tier 5 coinsurance percentage (typically 30–50%).
- Multiply by annual fill count (12 for monthly, 13 for every-28-day fills, 4 for every-three-months).
- Cap the total at the plan's individual out-of-pocket maximum (not to exceed $9,525 for 2027 on an ACA plan, and lower if you qualify for CSR).
- Add the plan's annual premium (after any ACA subsidy you qualify for).
Run your drugs through our Drug Cost Finder for a side-by-side on expected annual drug spend. Combine with our Plan Cost Calculator for the full post-subsidy comparison. If you qualify for subsidies, estimate them first with the ACA Subsidy Calculator, because higher-premium Silver plans often win on total annual cost once drug spend is factored in.
Three 2027 scenarios that show the tier 5 trap in action
Each scenario uses a realistic 2027 drug price, a realistic plan structure, and the 2027 ACA out-of-pocket maximum of $9,525 individual.
| Scenario | Plan A (specialty drug on tier 4, $150 copay) | Plan B (same drug on tier 5, 40% coinsurance) | Annual difference |
|---|---|---|---|
| Rheumatoid arthritis, biologic $4,200/month | $150 × 12 = $1,800 drug cost. Plus premium. | $1,680 × 5.7 months = $9,525 (hits OOPM). Zero drug cost for last 6 months of year, but OOPM is maxed, so medical visits also hit cap. Drug-only cost: $9,525. | Plan B costs $7,725 more on drugs alone. Plan A is better unless premium differential exceeds $644/month. |
| Multiple sclerosis, infused Ocrevus every 6 months, $65,000 per infusion | $150 × 2 = $300 drug cost. Plus premium. | 40% of $65,000 = $26,000 per infusion, but capped at $9,525 individual OOPM after first infusion. Drug + medical total $9,525. | Plan B costs $9,225 more. Only choose Plan B if its annual premium is $770+ lower per month than Plan A. |
| Hepatitis C cure course, Mavyret, $26,400 total (8 weeks) | $150 copay for the one course. | 40% of $26,400 = $10,560, capped at $9,525. | Plan B costs $9,375 more for a single treatment course, but at least you hit the cap and the rest of your care that year is free. |
Three real fixes if your drug is on tier 5 of every affordable plan
Fix 1: Request a formulary tier exception
Every ACA Marketplace plan must offer a formulary exception process. Within 72 hours of your doctor submitting the request (24 hours for urgent requests), the plan must decide whether to treat your drug as if it were on a lower tier. The standard argument: the lower-tier alternatives are not medically appropriate (because of side effects, contraindications, documented non-response, or your condition is not treated by the lower-tier drug). Your doctor files this; you follow up. Many approvals come within a week if clinical documentation is clean. If denied, appeal internally within 60 days, then externally to an independent review organization.
Fix 2: Use manufacturer copay assistance, with eyes open to accumulator/maximizer
Most biologic and specialty drug manufacturers offer copay cards that cap your out-of-pocket at $5–$25/month if you have commercial insurance (ACA Marketplace plans count as commercial). On paper, tier 5 and $1,680/fill becomes $5/fill. However, many 2027 plans use copay accumulator or copay maximizer programs that stop the manufacturer's payment from counting toward your plan deductible or OOPM. Under an accumulator, you pay $5 with the card but your deductible meter stays at zero all year. Under a maximizer, the manufacturer's full annual assistance (say $12,000) is spread across the year but never counts toward your plan limits. Both are legal in most states for ACA plans. Check the plan's SBC and benefit documents for “copay accumulator,” “copay adjustment,” or “variable copay” language. Our accumulator/maximizer guide covers both the state laws that ban them and the workarounds where they are still legal.
Fix 3: Shift metal tier to maximize OOPM-cap-and-escape
If your specialty drug will hit the OOPM no matter what, the plan's premium and out-of-pocket maximum together determine your total annual cost, not the drug-tier structure. In that case, the plan with the lowest combined (premium × 12) + OOPM wins. Silver plans with cost-sharing reductions (CSR) for enrollees under 250% FPL cap the OOPM at $3,250 (under 150% FPL), $3,250 (150–200%), or $7,725 (200–250%), often making a subsidized Silver dramatically cheaper than a Bronze with tier 5 coinsurance even though Bronze has lower premium. Read our CSR Silver plan guide for the income thresholds and the plan tier that qualifies.
Four common mistakes we are seeing in 2027 OEP week two
Mistake 1: Comparing 2027 formularies to 2026 memory
About 30% of specialty drug tier placements change between plan years industry-wide. If you take a specialty drug, assume your 2026 plan's 2027 formulary is different and verify it, even if you are being auto-renewed. Our 2027 auto-reenrollment guide covers how to intercept adverse formulary changes.
Mistake 2: Confusing the Medicare Part D $2,400 cap with ACA plans
The Inflation Reduction Act capped Medicare Part D out-of-pocket at $2,000 in 2025, $2,100 in 2026, and $2,400 in 2027. This cap only applies to Medicare Part D — standalone PDPs and Medicare Advantage with drug coverage. ACA Marketplace plans have no separate drug-only OOP cap. Your specialty drug costs count toward the plan's combined medical-and-drug OOPM of up to $9,525 for 2027.
Mistake 3: Using GoodRx or Mark Cuban Cost Plus as a backup plan
GoodRx and Cost Plus Drugs can be powerful tools for generic medications but almost never beat an ACA plan's specialty drug coverage for biologics. Specialty tier drugs typically have no generic substitute, and discount cards cannot bypass the manufacturer's price. For specialty drugs, your choice of plan is the choice; discount cards are not a fallback.
Mistake 4: Forgetting that tier 4 can also be coinsurance
Some 2027 plans place drugs on tier 4 with 25–30% coinsurance instead of a copay. Technically the drug is on a lower tier than tier 5, but 25% of $4,200 is $1,050 — much closer to tier 5 than to a $150 tier 4 copay. Always check the cost structure of the tier, not just the tier number. The SBC and the formulary PDF both disclose whether each tier uses copay or coinsurance.
What to do if you miss the December 15 deadline
You have three fallback paths:
- January 1–January 15, 2027. Final OEP deadline in most states. Change plans with a February 1 effective date. Our plan-switch guide covers the process.
- Qualifying Life Event SEP. A move, job loss, marriage, or income change opens a 60-day special enrollment window. Dissatisfaction with tier placement is not a SEP.
- Formulary exception from your current plan. If you cannot change plans, work within your existing plan: submit a tier exception request, pursue manufacturer copay assistance, and if denied, escalate through the plan's internal and external appeals process.
Related guides on this site
- Drug Cost Finder (search your drugs across 2027 plans) →
- Plan Cost Calculator (combined premium + OOPM analysis) →
- ACA Subsidy Calculator (2027 income thresholds) →
- Matching prescriptions to a 2027 ACA formulary →
- How to beat copay accumulator and maximizer programs →
- Appealing a step therapy “fail first” denial →
- How to compare 2027 ACA Marketplace plans →
- Family OOPM embedded vs aggregate trap →
- ACA cost-sharing reductions on Silver plans →
- How to lower prescription drug costs →